Terms: = Prostate cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Prognosis
52 results:
1. Dual targeting of the androgen receptor and PI3K/AKT/mtor pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract] [Full Text] [Related]
2. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.
Ali A; Mekhaeil B; Biziotis OD; Tsakiridis EE; Ahmadi E; Wu J; Wang S; Singh K; Menjolian G; Farrell T; Mesci A; Liu S; Berg T; Bramson JL; Steinberg GR; Tsakiridis T
Commun Biol; 2023 Sep; 6(1):919. PubMed ID: 37684337
[TBL] [Abstract] [Full Text] [Related]
3. High expression of ENPP2 is an independent predictor of poor prognosis in liver cancer.
Meng J; Ruan X; Wei F; Xue Q
Medicine (Baltimore); 2023 Aug; 102(31):e34480. PubMed ID: 37543832
[TBL] [Abstract] [Full Text] [Related]
4. Creation of a Prognostic Model Using Cuproptosis-Associated Long Noncoding RNAs in Hepatocellular Carcinoma.
Yang L; Jia X; Fu Y; Tian J; Liu Y; Lin J
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373132
[TBL] [Abstract] [Full Text] [Related]
5. FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/Akt/mtor signal pathway.
Azhati B; Reheman A; Dilixiati D; Rexiati M
Arch Biochem Biophys; 2023 Jun; 741():109604. PubMed ID: 37080415
[TBL] [Abstract] [Full Text] [Related]
6. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract] [Full Text] [Related]
7. AR and PI3K/AKT in prostate cancer: A Tale of Two Interconnected Pathways.
Tortorella E; Giantulli S; Sciarra A; Silvestri I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
[TBL] [Abstract] [Full Text] [Related]
8. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.
Ashrafizadeh M; Paskeh MDA; Mirzaei S; Gholami MH; Zarrabi A; Hashemi F; Hushmandi K; Hashemi M; Nabavi N; Crea F; Ren J; Klionsky DJ; Kumar AP; Wang Y
J Exp Clin Cancer Res; 2022 Mar; 41(1):105. PubMed ID: 35317831
[TBL] [Abstract] [Full Text] [Related]
9. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation.
Wang Z; Hulsurkar M; Zhuo L; Xu J; Yang H; Naderinezhad S; Wang L; Zhang G; Ai N; Li L; Chang JT; Zhang S; Fazli L; Creighton CJ; Bai F; Ittmann MM; Gleave ME; Li W
Neoplasia; 2021 Nov; 23(11):1147-1165. PubMed ID: 34706306
[TBL] [Abstract] [Full Text] [Related]
10. Genetic comprehension of organophosphate flame retardants, an emerging threat to prostate cancer.
Zhang X; Lu Z; Ren X; Chen X; Zhou X; Zhou X; Zhang T; Liu Y; Wang S; Qin C
Ecotoxicol Environ Saf; 2021 Oct; 223():112589. PubMed ID: 34358932
[TBL] [Abstract] [Full Text] [Related]
11. Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review.
Jahan N; Jones C; Rahman RL
Mol Cell Endocrinol; 2021 Jul; 531():111324. PubMed ID: 34000352
[TBL] [Abstract] [Full Text] [Related]
12. The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
Rafat M; Moraghebi M; Afsa M; Malekzadeh K
Hum Cell; 2021 Jul; 34(4):1051-1065. PubMed ID: 33997944
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Zhang C; Ren X; Zhang W; He L; Qi L; Chen R; Tu C; Li Z
Bioengineered; 2020 Dec; 11(1):1112-1123. PubMed ID: 33124951
[TBL] [Abstract] [Full Text] [Related]
14. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract] [Full Text] [Related]
15. Circular RNA circMBOAT2 promotes prostate cancer progression via a miR-1271-5p/mtor axis.
Shi J; Liu C; Chen C; Guo K; Tang Z; Luo Y; Chen L; Su Y; Xu K
Aging (Albany NY); 2020 Jul; 12(13):13255-13280. PubMed ID: 32645691
[TBL] [Abstract] [Full Text] [Related]
16. Knockdown of FBP1 enhances radiosensitivity in prostate cancer cells by activating autophagy.
Li XR; Zhou KQ; Yin Z; Gao YL; Yang X
Neoplasma; 2020 Sep; 67(5):982-991. PubMed ID: 32453596
[TBL] [Abstract] [Full Text] [Related]
17. Deregulated PTEN/PI3K/AKT/mtor signaling in prostate cancer: Still a potential druggable target?
Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
[TBL] [Abstract] [Full Text] [Related]
18. Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients.
Hu D; Jiang L; Luo S; Zhao X; Hu H; Zhao G; Tang W
J Transl Med; 2020 Apr; 18(1):160. PubMed ID: 32264916
[TBL] [Abstract] [Full Text] [Related]
19. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mtor pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract] [Full Text] [Related]
20. Mechanism of Anti-cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent prostate cancer.
Abd Wahab NA; Lajis NH; Abas F; Othman I; Naidu R
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32131560
[TBL] [Abstract] [Full Text] [Related]
[Next]
